SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS)

25 filings reported holding SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2024.
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3.14M shares of 51.7M outstanding shares and own 6.07% of the company stock.
Largest 10 shareholders include BVF INC/IL (918K shares), RTW INVESTMENTS, LP (635K shares), MARSHALL WACE, LLP (459K shares), Sessa Capital IM, L.P. (458K shares), VANGUARD GROUP INC (276K shares), HB Wealth Management, LLC (109K shares), GEODE CAPITAL MANAGEMENT, LLC (67.5K shares), MILLENNIUM MANAGEMENT LLC (51.9K shares), Pathstone Holdings, LLC (50.7K shares), and FIRST MANHATTAN CO. LLC. (24.6K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.